Biotechnology | BAHATI

A long-awaited emotional and financial boost for China’s cancer patients

Bahati 15 October 2018

By Chermaine Lee

Imagine this: if your beloved one was diagnosed of a fatal cancer, dealing with heartbreaks aside, you had to start borrowing money for the treatment. Taking a few more part-time jobs was barely enough to pay for the expensive drugs, not to mention the ever-growing debts.

ASEAN, Asia Society, Biotechnology, China, Development, Healthcare, Hong Kong

Tariffs Notwithstanding, Globalization Alive and Well in Healthcare

Bahati 5 October 2018

By Alfred Romann

The backlash against global trade and the resurgence of protectionism is increasingly evident, mostly out of the U.S. This push flies in the face of decades of increasingly fluent globalization.

ASEAN, Biotechnology, Business, Development, Economics, Healthcare, Japan, South Korea globalization, Healthcare, international trade, Japan, medical device, Nipro, Samsung Electronics, South Korea

South Korea takes steps to lower pharma prices

Alfred Romann 4 May 2018

New measures put pressure on drug makers, importers and distributors

South Korea’s latest moves to make drugs more affordable are slowing down the growth of the pharma market in the country and maybe hurting sales of new and innovative drugs.

BMI Research predicts South Korean pharmaceutical will grow at 2.4% for the next 10 years, 1% less than expected. Elise Mak wrote about the changes in BioWorld (paywall) on May 4.

Biotechnology, Business, Economics, Healthcare, South Korea biotechnology, drug prices, pharma, South Korea

A dengue vaccine… finally

Alfred Romann 11 December 2015

Mexico becomes first country to approve new vaccine, 20 others to follow

It has been a long time coming, but the first dengue vaccine should hit the market next year in Mexico and, with any luck, in about 20 markets over the next couple of years.

The Philippines could be next.

ASEAN, Biotechnology, Healthcare, Latin America Dengue, Mexico, Phillippines, Vaccines

R&D spend driving China pharma co’s

Alfred Romann 17 September 2015

Companies are narrowing the gap

China is not a powerhouse of innovation, yet, but it is certainly trying to pay its way into that particular status. This willingness to spend in R&D – to pay to talent, buy innovative companies and seek out new technologies – is particularly visible in the pharmaceutical and biotechnology space. And it is working.

Biotechnology, China, Healthcare biotechnology, China, Healthcare, innovation, research, spending

Australia’s largest life science fund

Bahati 13 May 2015

Australia’s life science sector outperforms in research… falls short on commercialisation.

It is no surprise that the life science sector including pharmaceutical, medical devices etc. is one of the hottest investment destinations. Last month, Australian investment company Brandon Capital closed the largest life science fund to date in Australia after raising A$200 million (US$155 million). The fund is set to fill the funding gap of the country’s medical technology commercialisation.

Biotechnology, Business Australia, BioWorld, Healthcare

China Issues Biosimilar Guidelines Draft

Bahati 3 December 2014

A long-awaited set of guidelines for a billion-dollar market.

After years of waiting, Chinese biosimilar makers will soon have a set of guidelines to follow.

This post on Thomson Reuters Life Sciences Connect news blog (HERE) outlines the industry’s reaction to the draft biosimilar guidelines.

Biotechnology, China, Economics, Healthcare